Establishment Labs (NASDAQ:ESTA) Sees Large Volume Increase

Establishment Labs Holdings Inc. (NASDAQ:ESTA) saw an uptick in trading volume on Tuesday . 276,145 shares changed hands during mid-day trading, a decline of 24% from the previous session’s volume of 363,283 shares.The stock last traded at $40.71 and had previously closed at $43.27.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on the company. Stephens reaffirmed an “overweight” rating and issued a $68.00 price objective on shares of Establishment Labs in a research report on Wednesday, August 7th. Citigroup increased their price target on Establishment Labs from $41.00 to $45.00 and gave the company a “neutral” rating in a report on Thursday, August 22nd. JPMorgan Chase & Co. cut their price objective on shares of Establishment Labs from $61.00 to $50.00 and set an “overweight” rating on the stock in a research report on Wednesday, August 7th. Finally, Mizuho lifted their price target on shares of Establishment Labs from $65.00 to $70.00 and gave the stock a “buy” rating in a research note on Thursday, June 6th. One analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $56.60.

Establishment Labs Stock Down 12.4 %

The firm has a market capitalization of $1.04 billion, a PE ratio of -12.74 and a beta of 1.20. The company has a debt-to-equity ratio of 4.30, a quick ratio of 2.91 and a current ratio of 4.44. The company has a fifty day simple moving average of $43.02 and a two-hundred day simple moving average of $47.27.

Establishment Labs (NASDAQ:ESTA) last announced its quarterly earnings results on Tuesday, August 6th. The company reported ($0.62) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.11). The firm had revenue of $44.12 million for the quarter, compared to analysts’ expectations of $43.10 million. Establishment Labs had a negative net margin of 54.97% and a negative return on equity of 220.67%. The business’s quarterly revenue was down 9.2% on a year-over-year basis. During the same quarter in the prior year, the business posted ($0.65) EPS. Analysts forecast that Establishment Labs Holdings Inc. will post -2.2 EPS for the current fiscal year.

Insider Buying and Selling at Establishment Labs

In other Establishment Labs news, CEO Quiros Juan Jose Chacon sold 3,641 shares of Establishment Labs stock in a transaction dated Thursday, July 11th. The stock was sold at an average price of $45.04, for a total value of $163,990.64. Following the transaction, the chief executive officer now owns 210,735 shares in the company, valued at $9,491,504.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 11.44% of the stock is owned by insiders.

Institutional Investors Weigh In On Establishment Labs

Several institutional investors have recently added to or reduced their stakes in the business. Capital Research Global Investors acquired a new stake in Establishment Labs in the first quarter worth about $45,888,000. William Blair Investment Management LLC boosted its holdings in Establishment Labs by 14.5% in the second quarter. William Blair Investment Management LLC now owns 481,572 shares of the company’s stock worth $21,883,000 after acquiring an additional 60,848 shares in the last quarter. Bamco Inc. NY boosted its holdings in Establishment Labs by 28.4% in the first quarter. Bamco Inc. NY now owns 429,775 shares of the company’s stock worth $21,876,000 after acquiring an additional 95,000 shares in the last quarter. Sofinnova Investments Inc. boosted its holdings in Establishment Labs by 204.1% in the second quarter. Sofinnova Investments Inc. now owns 429,244 shares of the company’s stock worth $19,505,000 after acquiring an additional 288,082 shares in the last quarter. Finally, First Turn Management LLC acquired a new stake in Establishment Labs in the second quarter worth about $16,812,000. Institutional investors and hedge funds own 72.91% of the company’s stock.

Establishment Labs Company Profile

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.